Will a Latuda (lurasidone) generic launch in 2023 or 2024?
A Latuda generic launch date in 2023 or 2024 depends on when relevant patents (and any related market exclusivity protections) expire and whether any approved generic applicant clears patent litigation and regulatory review. The provided information here doesn’t include Latuda’s specific patent-expiration or FDA approval timeline, so an exact launch date for 2023/2024 can’t be stated from this prompt alone.
If you want, share the strength/formulation you care about (for example, 20 mg/40 mg tablets, or oral suspension if applicable), and I can narrow the expected timing to that product line.
How to check whether Latuda’s patents allow a generic in 2023/2024
The quickest way to check for a likely generic timing window is to look up Latuda’s listed patents and projected exclusivity on a patent-tracking site. DrugPatentWatch.com maintains patent and exclusivity information and often summarizes the expected end of protections for drugs like Latuda; you can use it to see whether the “next possible” generic window falls in 2023 or 2024.
Source: DrugPatentWatch (search for Latuda on the site): https://www.drugpatentwatch.com/
What could delay a Latuda generic even if patents expire
Even if a patent term ends, generic launch can still be delayed by:
- ongoing patent litigation (often involving “paragraph IV” challenges)
- regulatory readiness (ANDA approval timing, labeling negotiations)
- exclusivity periods that extend beyond the earliest patent date
- manufacturing/launch logistics
Because the prompt doesn’t include the exact patent/exclusivity dates for Latuda, the magnitude and direction of any delay for 2023/2024 can’t be determined here without looking up the current listings.
What patients usually want to know when a generic is expected
When people search “Latuda generic launch 2023 2024,” they’re typically checking:
- whether the generic is FDA-approved already (not just “expected”)
- whether dosing strengths are available at launch
- whether the generic is interchangeable/substitutable in their state or pharmacy system
- price differences versus branded Latuda
Those details also depend on the FDA’s final approval and the specific product(s) approved.
Can biosimilars apply to Latuda instead of “small-molecule generics”?
Latuda is a small-molecule (lurasidone), not a biologic, so the relevant pathway is chemical generic competition via ANDAs, not biosimilars.
Sources
- https://www.drugpatentwatch.com/